AAV dual-payload gene therapy injected directly into high-grade glioma to kill tumor cells and stimulate immune attack.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1/2, dose-finding and expansion trial of TGX-007, an AAV vector carrying two therapeutic genes (HSV-tk and IL-12) delivered by direct intratumoral injection. HSV-tk converts the oral prodrug valaciclovir into a cytotoxic agent to kill proliferating tumor cells, while IL-12 is intended to activate local anti-tumor immunity. The Phase 1 portion defines safety and an optimal biological dose, followed by further safety and preliminary efficacy assessment in Phase 2 in newly diagnosed or first-recurrence glioblastoma patients who are eligible for surgery. Patients receive the intratumoral injection at the time of indicated debulking surgery and then standard chemoradiotherapy or follow-up as appropriate.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18-70 years
* Karnofsky performance status ≥70
* Newly diagnosed patients: Unifocal, unilateral high-grade glioma based on MRI
* Recurrent patients: First radiological progression (as determined by the multidisciplinary team \[MDT\]) of GBM previously treated with standard care surgery and chemoradiotherapy. Patients must have a prior confirmed histological/molecular diagnosis of GBM
* Newly diagnosed patient: suitable for six weeks of chemoradiotherapy followed by six months of adjuvant temozolomide (Stupp protocol)
* Debulking surgery is indicated for optimal patient care
* Able to swallow oral medication
* Willing to avoid live vaccines
* Adequate organ function
* Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to Day 0.
* All patients must agree to practice true abstinence or to use highly effective contraception
* Patient is willing and able to give informed consent for participation in the study

Exclusion Criteria:

* Patient who is pregnant, lactating or planning pregnancy during the course of the study
* Immunodeficiency or active auto-immune disease requiring systemic therapy.
* Active viral, bacterial or fungal infection requiring concurrent antivirals or antibiotics within 7 days of surgery
* Live vaccine within 28 days prior to Day 0
* Use of immunosuppressant or immune modulatory medicines within 28 days prior to Day 0
* History of tuberculosis infection or chest x-ray or computed tomography (CT) chest showing radiological evidence of previous tuberculosis infection
* Received previous treatment with a gene therapy
* Significant history of a central nervous system disorder that, in the opinion of the Investigator, would preclude enrolment
* Major surgery within 28 days prior to Day 0. A stereotactic biopsy is permitted
* Known hypersensitivity or contraindications to valaciclovir, gadolinium, or any excipients for TGX-007
* Contraindication to MRI with gadolinium
* Any condition expected to interfere with the intended timing of debulking surgery
* Previous non-glioma cancer within 3 years (other than treated squamous/basal cell skin cancer, treated early-stage cervical cancer or treated/biochemically stable, organ confined prostate cancer)
* Any other significant disease or disorder which, in the opinion of the Investigator, may put the patient at risk because of participation in the study or may influence the results of the study or the patient's ability to participate in the study
* Patients who have participated in another research study involving an investigational product in the past 12 weeks or 5 half-lives of the product
* Any psychological, familial, sociological, or geographical consideration potentially hampering compliance with the study protocol and follow up schedule; these conditions should be discussed with the patient before registration in the study
* Unwilling to allow their general practitioner, if appropriate, to be notified of participation in the study

Newly diagnosed patients only:

* Any prior therapy for glioma
* Intended use of tumour treating fields

Recurrent patients only:

* Prior toxicities from anti-cancer agents or radiotherapy which have not recovered to ≤Grade 1 severity
* Intended use of tumour treating fields

Where it's running

• Ohio State University Hospital
  Columbus, Ohio, United States Recruiting
• Royal Infirmary of Edinburgh
  Edinburgh, United Kingdom Recruiting

Study contacts

• Study coordinator: Project Management
• Email: Contact@trogenix.com
• Phone: +44131 287 5960

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted radioligand therapy for recurrent glioblastoma with Lu-177 XT771

  This early-phase study tests whether a radiolabeled medicine (Lu-177 XT771) delivered directly into the tumor cavity is safe and tolerable for adults with recurrent glioblastoma.

  Recruiting at 2 sites Early Phase 1 Beijing Tiantan Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07648823

• Dual-target CAR-NK therapy for adults with recurrent or progressive glioblastoma and other high-grade gliomas

  This study will try giving dual-target CAR-NK cells into the surgical cavity to see if they can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07551336

• Silevertinib plus temozolomide for newly diagnosed GBM with unmethylated MGMT and EGFRvIII

  This trial tests whether adding silevertinib to standard temozolomide helps people with newly diagnosed glioblastoma that have EGFRvIII and an unmethylated MGMT promoter live longer without the cancer getting worse.

  Recruiting at 38 sites Phase 2 Black Diamond Therapeutics, Inc. · Birmingham, Alabama and 37 other locations · NCT07326566

• Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents

  This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.

  Recruiting Phase 1/2 Fundación de investigación HM · Boadilla del Monte, Madrid · NCT06607692

• BRiTE: a brain-penetrant bispecific T cell engager for EGFRvIII-positive glioblastoma

  This Phase 1 study tests the safety of BRiTE, a brain-delivered bispecific T cell engager, in adults with newly diagnosed or recurrent EGFRvIII-positive glioblastoma.

  Recruiting Phase 1 Duke University · Durham, North Carolina · NCT04903795

• Brain connectome project in adults with brain glioma undergoing surgery

  This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.

  Recruiting Northwell Health · New York, New York · NCT07927595

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.